MetLife, Inc. research snapshot
MET AI stock analysis currently reads MetLife, Inc. as a diversified global insurer and employee benefits franchise with stronger Q1 2026 adjusted earnings, broad segment growth, active share repurchases, and a rising dividend. At the July 8, 2026 data cutoff, MET traded near $91.67 with a verified market capitalization near $58.98 billion. The favorable signal is operating momentum across Group Benefits, Retirement and Income Solutions, Asia, Latin America, EMEA, and MetLife Investment Management. The caution is valuation and cycle risk because insurance earnings can move with rates, credit marks, underwriting assumptions, private equity returns, and market risk benefit remeasurement. This MET AI stock analysis is informational research, not investment advice.
Current price
$91.67
Market cap
$58.98 billion
AI score
73 / 100
Rating
Global insurer with solid capital return and improving adjusted earnings, but limited margin of safety near a fresh high
Trend status
Bullish trend above the 50-day and 200-day moving averages, with momentum close to the upper end of its recent range
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | MetLife sells life insurance, employee benefits, annuities, retirement income products, and asset management services where customers pay for risk transfer, income protection, savings, and institutional investment expertise. | High |
| Moat | The moat comes from brand, employer distribution, regulatory licenses, actuarial data, global scale, long-term customer relationships, investment management capabilities, and capital strength. | Medium-high |
| Management | Michel Khalaf has led a disciplined capital-return and portfolio strategy, including the New Frontier plan, PineBridge acquisition, dividend growth, and over $1.1 billion returned to shareholders in Q1 2026. | Medium-high |
| Financial trend | Q1 2026 net income rose 30% to $1.1 billion, adjusted earnings rose 18% to $1.6 billion, PFOs rose 5% to $14.3 billion, and adjusted EPS rose 23% to $2.42. | High |
| Valuation | At $91.67, financial_rigor.py calculates 9.19x 2026 expected EPS of $9.98, 2.42x Q1 2026 book value per share of $37.92, 0.76x revenue per share, and a 2.59% dividend yield. | Medium-high |
| Technical trend | MET traded above the 50-day moving average near $83.21 and 200-day moving average near $78.59, with RSI near 68.18 and a July 7 close at a new high. | Medium-high |
| Risk level | Main risks are investment losses, commercial mortgage credit, private equity return normalization, rate shocks, underwriting misses, reserve assumptions, foreign currency, regulation, and valuation compression. | Medium-high |
| AI confidence | High for descriptive and reported data. Medium for the forecast because insurance stocks can rerate quickly when rates, credit spreads, equity markets, or actuarial assumptions change. | High data confidence |
| Investment certainty | Medium certainty. MET is a well-disclosed global insurer with improving adjusted earnings, but the stock already reflects a stronger capital-return and earnings story. | Medium |
MET AI stock forecast
The MET AI stock forecast uses scenario math around the $91.67 quote and 2026 expected EPS of $9.98. A three-year framework audited with financial_rigor.py produced a bullish value near $150.90, a base value near $112.30, and a bearish value near $63.80 before dividends. These are scenario outputs, not a reliable prediction of MetLife stock price.
$145 to $155
More likely if adjusted EPS compounds near high single digits, private equity and investment income remain supportive, Group Benefits and Asia keep growing, buybacks reduce share count, and investors value MET near 12x earnings.
$108 to $116
More likely if EPS grows near a mid single digit pace, adjusted PFO growth stays positive, capital returns continue, credit losses remain manageable, and the market applies about 10x earnings.
$60 to $68
More likely if investment losses widen, credit stress rises in mortgage or private assets, variable investment income normalizes lower, underwriting assumptions disappoint, or investors compress MET toward 7x earnings.
MET AI technical analysis
MET AI technical analysis was bullish as of the July 8, 2026 data cutoff, but not an early low-risk entry. StockAnalysis listed a July 7, 2026 price of $91.67, 50-day moving average near $83.21, 200-day moving average near $78.59, RSI near 68.18, and 20-day average volume near 3.85 million shares. MarketWatch reported the July 7 close as a fresh 52-week high with volume below its 50-day average. Because this static page does not fetch live data, confirm all levels on a current chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $91.67 | July 7, 2026 close used for this static page and market cap verification. |
| Near support | $83 to $84 | The 50-day moving average zone is the first trend support area after the move to a new high. |
| Secondary support | $78 to $79 | The 200-day moving average zone is the main long-term trend support reference. |
| Near resistance | $92 to $93 | The stock closed near a fresh 52-week high, so resistance is defined by failed follow-through above the recent high zone. |
| 50-day moving average | $83.21 | StockAnalysis moving-average snapshot at the cutoff. |
| 200-day moving average | $78.59 | Price was above this long-term moving average, supporting a positive primary trend. |
| Momentum | RSI 68.18 | Momentum was strong and close to overbought, which supports the trend but raises pullback risk. |
| Volume | About 3.85 million shares | 20-day average volume from StockAnalysis. MarketWatch reported July 7 volume near 3.0 million, below its 50-day average. |
| Volatility | Beta 0.78 | StockAnalysis listed a five-year beta below the market, but insurer-specific events can still move the stock sharply. |
| Invalidation | Close below $83, then $78 | A close below the 50-day area weakens the near-term setup. A break below the 200-day area would challenge the primary trend. |
MET AI trading strategy
The MET AI trading strategy is a rules-based framework for a global life insurer and benefits company, not personalized advice. It combines live chart confirmation with earnings quality, adjusted PFO growth, investment income, capital return, book value, and credit-risk monitoring.
Watch for MET to hold above the $83 area and extend above the $92 to $93 high zone with stronger than average volume, while financial-sector breadth and insurer peer performance remain supportive.
A failed breakout or daily close below the 50-day moving average zone should reduce confidence in the near-term trend setup.
If MET pulls back toward $83 or the $78 to $79 area without deterioration in adjusted earnings, credit marks, holding company liquidity, dividend capacity, or management guidance, compare the pullback with the long-term franchise thesis.
Do not average down solely because MET is a large insurer. Long-duration liabilities, credit marks, and rate shocks can change the equity story quickly.
Track Q2 2026 earnings, adjusted EPS, adjusted PFO growth excluding pension risk transfers, net investment income, variable investment income, book value per share, adjusted ROE, share repurchases, dividend policy, mortgage loan ACL, and management comments on New Frontier targets.
Lower the rating if adjusted earnings depend mainly on volatile investment returns, credit losses rise faster than capital buffers, book value weakens, or buybacks slow while valuation stays near recent highs.
Investment research summary
MetLife helps employers, households, retirees, and institutions transfer mortality, morbidity, savings, income, and investment risks that are hard for customers to manage alone.
The moat is brand trust, employer channel access, regulatory licensing, actuarial experience, global scale, investment management depth, data from large policy pools, and customer switching friction in benefits and retirement plans.
The thesis can fail if rates move against liabilities, credit losses rise, private equity returns normalize lower, actuarial assumptions prove too optimistic, regulation limits capital return, or the market stops valuing buybacks and adjusted earnings.
Michel Khalaf and the team should be judged by capital allocation, risk discipline, adjusted ROE, book value growth, dividend coverage, integration of PineBridge, and whether New Frontier targets are met without taking hidden balance-sheet risk.
Insurance demand is durable because aging populations, employer benefits, retirement income needs, and risk transfer remain necessary. The industry is not a simple growth curve because results still depend on rates, capital markets, regulation, underwriting, and credit cycles.
At about 9.19x expected 2026 EPS and near a new high, MET is priced as a healthy insurer rather than a distressed value stock. Margin of safety improves if the stock pulls back while adjusted earnings, liquidity, dividends, buybacks, and credit quality remain intact.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price | $91.67 close on July 7, 2026 | StockAnalysis MET market cap page | July 8, 2026 |
| Market capitalization | $58.98 billion, verified as $91.67 x 643.44 million shares | financial_rigor.py and StockAnalysis | July 8, 2026 |
| Shares outstanding | 643.44 million | StockAnalysis statistics page | July 8, 2026 |
| FY 2025 revenue | $77.084 billion | Macrotrends and StockAnalysis cross-validation | July 8, 2026 |
| FY 2025 net income | $3.173 billion | Macrotrends and StockTitan cross-validation | July 8, 2026 |
| Q1 2026 net income | $1.1 billion, or $1.74 per share | MetLife Q1 2026 earnings release | July 8, 2026 |
| Q1 2026 adjusted earnings | $1.6 billion, or $2.42 per share | MetLife Q1 2026 earnings release | July 8, 2026 |
| Q1 2026 PFOs | $14.3 billion, up 5% | MetLife Q1 2026 earnings release | July 8, 2026 |
| Q1 2026 book value per share | $37.92, adjusted book value per share $57.41 | MetLife Q1 2026 earnings release | July 8, 2026 |
| 2026 expected EPS used for scenarios | $9.98 per share | MarketBeat MET analyst estimate snapshot | July 8, 2026 |
| Holding company cash and liquid assets | $3.9 billion at Q1 2026 quarter end | MetLife Q1 2026 earnings release | July 8, 2026 |
| Common dividend | $0.5925 quarterly dividend declared for Q2 2026 | MetLife dividend increase release | July 8, 2026 |
| Technical snapshot | 50-day moving average $83.21, 200-day moving average $78.59, RSI 68.18, 20-day average volume 3.85 million | StockAnalysis statistics page | July 8, 2026 |
This MET AI stock analysis is an informational research tool only and is not investment advice, a recommendation, or a guarantee of future performance. Forecast scenarios are based on available public data as of the stated cutoff date, can be wrong, and should be checked against current filings, live market prices, and your own risk constraints.
